You are here: Industry Insights > IND

News List

Oxford BioTherapeutics Receives IND Clearance for OBT076 americanpharmaceuticalreview
December 24, 2018
Oxford BioTherapeutics has received US Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) for OBT076.....
Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China pharmafocusasia
December 17, 2018
Innovent Biologics, Inc. and Incyte today announced that the companies, through their respective subsidiaries, have entered into a strategic collaboration agreement for .....
Generex receives IND approval from FDA biospectrumasia
December 17, 2018
The combination study builds on previous clinical studies of both AE37 and Keytruda. AE37, a cancer vaccine, was the subject of a 300 patient prospective, randomized and single-blinded Phase II study in patients with breast cancer.
Mirati Announces Clearance of IND Application for MRTX849 Trial americanpharmaceuticalreview
December 03, 2018
Mirati Therapeutics announced the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug (IND) application for .....
FDA warns investigator for violating clinical hold endpts
November 28, 2018
The US Food and Drug Administration (FDA) earlier this month warned Faro Owiesy, a physician and clinical investigator at the California-based Corona Doctors Medical Clinics.....
Biohaven Announces Submission of IND for BHV-3500 americanpharmaceuticalreview
September 13, 2018
Biohaven has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate the safety and tolerability of BHV-3500, the first small molecule calcitonin gene-related peptide (CGRP) receptor antagonist to
FDA Approves IND for ADG-106 Study americanpharmaceuticalreview
July 11, 2018
Adagene has received notification from the FDA to proceed on its Investigational New Drug (IND) application to study its lead product (ADG-106) in patients with advanced solid tumors and non-Hodgkin lymphoma.
MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of RMAT Designated AmnioFix® Injectable For The Treatment Of Osteoarthritis Of The Knee biospace
March 29, 2018
MiMedx Group, Inc. today announced that the first patient has been enrolled in the Company's Phase 2B Investigational New Drug (IND) clinical trial
FDA Approves IND of AmnioFix americanpharmaceuticacreview
October 18, 2017
MiMedx Group announced the company has been notified by the Food and Drug Administration (FDA) that its Investigational New Drug (IND) Phase 2B clinical study for osteoarthritis of the knee may proceed.
Big Pharma ally Atreca scoops $35M as I-O assets near IND fiercebiotech
August 18, 2017
Atreca plans to pick a clinical candidate by the end of the year.

Previous page 1 2 3 4 Next page